Holen Sie sich die Stockscreener-App
5.16
21.70%
0.92
Handel nachbörslich:
5.24
0.08
+1.55%
I Mab Adr Aktie (IMAB) Neueste Nachrichten
Kimball Electronics Posts Better-Than-Expected… - inkl
The Psychology of I-Mab ADR Inc. (IMAB) Price Performance: Understanding Market Sentiment - investchronicle.com
I-Mab completes enrollment for givastomig trial ahead of schedule By Investing.com - Investing.com South Africa
I-Mab completes enrollment for givastomig trial ahead of schedule - Investing.com
Adverse Reactions to Tremelimumab, Durvalumab in Liver Cancer - BIOENGINEER.ORG
Cardiovascular Adverse Drug Reactions of Anti-Calcitonin Gene-Related Peptide Monoclonal Antibodies for Migraine Prevention: An Analysis from the European Spontaneous Adverse Event Reporting System. - Physician's Weekly
I-Mab ADR: Analyzing IMAB Stock Trends - investchronicle.com
I-Mab Announces Pricing of $65 Million Underwritten Offering of American Depositary Shares - GlobeNewswire Inc.
I-Mab ADR (IMAB) Stock: Navigating a Year of Stock Volatility - investchronicle.com
I-Mab acquires Bridge Health to strengthen givastomig development By Investing.com - Investing.com South Africa
I-Mab acquires Bridge Health to strengthen givastomig development - Investing.com India
Best Income Stocks to Buy for July 16th - The Globe and Mail
I-MAB files 6-K to amend US$21M ADS shelf registration | BQ SEC FilingForm 6-K - Stock Titan
I-Mab reports 83% response rate for givastomig in gastric cancer study - Investing.com India
I-Mab’s givastomig shows promising results in gastric cancer study - Investing.com
I-Mab stock maintains buy rating at H.C. Wainwright on strong cancer data - Investing.com
I-Mab reports 71% response rate for gastric cancer drug in trial - Investing.com
H.C. Wainwright reiterates buy rating on I-Mab stock ahead of key data By Investing.com - Investing.com South Africa
H.C. Wainwright reiterates buy rating on I-Mab stock ahead of key data - Investing.com
I-Mab at H.C. Wainwright: Strategic Shift Towards U.S. Operations - Investing.com
I-Mab at H.C. Wainwright: Strategic Shift Towards U.S. Operations By Investing.com - Investing.com South Africa
Market Momentum: Abpro Holdings Inc (ABP) Registers a 3.72 Increase, Closing at 0.22 - DWinneX
Unity Software Inc’s Market Journey: Closing Strong at 24.40, Up 3.13 - DWinneX
I-Mab Sponsored ADR (IMAB)'s Technical Outlook is Bright After Key Golden Cross - MSN
I-Mab regains Nasdaq compliance as shares maintain $1 minimum bid - Investing.com India
I-Mab Regains Compliance with Nasdaq Minimum Bid Price Requirement - Yahoo Finance
Figure 1. Protein and mRNA expressions of P-glycoprotein in BEL-7402... - researchgate.net
Willdan Group, Inc.'s (NASDAQ:WLDN) Stock Has Seen Strong Momentum: Does That Call For Deeper Study Of Its Financial Prospects? - Yahoo Finance
Can This Unstoppable Stock Join Microsoft, Nvidia, Apple, Amazon, Alphabet, Meta Platforms, and Tesla in the $1 Trillion Club? - Yahoo Finance
Graphjet Technology Discloses Notice from Nasdaq - Yahoo Finance
B. Riley Financial granted extension from Nasdaq regarding listing rules - Yahoo Finance
I-Mab Sponsored ADR (IMAB) is a Great Momentum Stock: Should You Buy? - sharewise
All You Need to Know About PTC Therapeutics (PTCT) Rating Upgrade to Buy - Yahoo Finance
Asian Stocks Shine As Biotech And Financials Lead Gains - Finimize
Lyra Stock Soars 356% in a Week on Strong Rhinosinusitis Study Success - Yahoo Finance
I-Mab to Participate in the H.C. Wainwright “HCW@Home” Series - Yahoo Finance
I-Mab stock surges on Lucid Capital’s buy rating initiation By Investing.com - Investing.com South Africa
I-Mab stock surges on Lucid Capital’s buy rating initiation - Investing.com
Lucid Capital sets I-Mab stock Buy rating, $5 target on cancer drug potential - Investing.com
I-Mab’s Financial Report Highlights Givastomig Progress - TipRanks
I-Mab Reports First Quarter 2025 Financial Results and Provides Business Update - Yahoo Finance
I-Mab Announces Encouraging Phase 1b/2 Study Results of Patients with Advanced NSCLC Receiving Uliledlimab and Toripalimab Combination Therapy at ASCO 2023 - Barchart.com
I-Mab Announces Publication of Claudin18.2 x 4-1BB Bispecific Antibody Givastomig in JITC - Barchart.com
After Plunging -20.33% in 4 Weeks, Here's Why the Trend Might Reverse for IMab (IMAB) - Yahoo Finance
After Plunging -19.7% in 4 Weeks, Here's Why the Trend Might Reverse for IMab (IMAB) - Yahoo Finance
I-Mab at Needham Conference: Strategic Transformation Unveiled - Investing.com
I-Mab at Needham Conference: Strategic Transformation Unveiled By Investing.com - Investing.com South Africa
I-Mab’s Transformative Year: Financial and Strategic Highlights - TipRanks
I-Mab stock price target lowered to $7 at H.C. Wainwright By Investing.com - Investing.com South Africa
I-Mab stock price target lowered to $7 at H.C. Wainwright - Investing.com India
0.11%
1.56%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):